RxDoctor Payments Data

Erik Mordukhay

Adult Health · Brooklyn, NYNPI 1851464853

Payments from drug & device makers

$1,649in general payments, 2019–2025

Across 66 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$314
  • Celltrion, Inc.$300
  • Novo Nordisk$220
  • Astellas Pharma US Inc$116
  • Bayer$104
  • Amgen$91
  • plus $504 from 13 others

What the payments were for

  • Speaking & faculty fees$473%
  • Food & beverage$1,30279%
  • Gifts$30018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,649 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$11,362
Medicare patients
36
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide113$113,108
MounjaroTirzepatide109$112,987
OzempicSemaglutide114$111,019
JardianceEmpagliflozin156$101,749
LinzessLinaclotide183$96,958
Diclofenac Sodium155$84,526
JanuviaSitagliptin Phosphate101$62,115
KerendiaFinerenone64$46,103
CreonLipase/Protease/Amylase40$45,700
EliquisApixaban70$39,477
UbrelvyUbrogepant23$34,853
Breo ElliptaFluticasone/Vilanterol79$30,213
JanumetSitagliptin Phos/Metformin Hcl39$24,798
LyricaPregabalin28$22,721
XareltoRivaroxaban37$22,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$314$226,095222 claims
AbbVieLinzess, Creon, Ubrelvy, Synthroid$36$180,434302 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$25$126,258205 claims
Novo NordiskOzempic$220$111,019114 claims
PfizerEliquis, Lyrica$70$62,19898 claims
BayerKerendia$104$46,10364 claims
Astellas Pharma US IncMyrbetriq$116$11,33421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.

Other adult health in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →